Haven Malish, MD
Pulmonary Disease · Bismarck, NDNPI 1831283936
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 44.6% of the total. Among pulmonary disease clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $90.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$7K
- Intuitive Surgical$7K
- AstraZeneca$244
- Melinta Therapeutics, LLC$226
- Harmony Biosciences LLC$218
- GSK$168
- plus $1K from 25 others
What the payments were for
- Travel & lodging$4,90630%
- Food & beverage$5,72635%
- Education$5,51334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 84 | $7,197 |
| Intuitive Surgical | 10 | $6,971 |
| AstraZeneca(2 entities) | 7 | $244 |
| Melinta Therapeutics, LLC | 7 | $226 |
| Harmony Biosciences LLC | 11 | $218 |
| GSK | 6 | $168 |
| Mallinckrodt Hospital Products Inc. | 4 | $136 |
| Grifols USA, LLC | 9 | $125 |
| Merck | 8 | $123 |
| Boehringer Ingelheim | 2 | $123 |
| Insmed, Inc. | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 4 | $84 |
| Abiomed | 1 | $61 |
| Baxter Healthcare | 3 | $47 |
| Philips North America LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $23 |
| UCB, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Fisher & Paykel Healthcare Inc | 1 | $12 |
| AbbVie | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,681
- Inspire Upper Airway Stimulation System$4,016
- Inspire$1,612
- Rezzayo$125
- OFEV$106
- NUCALA$102
How this compares
$16,145 in reported general payments places this provider in the 90th percentile of 31 pulmonary disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $22,665 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $13,272 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,342 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,805 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $389 |
| Montelukast Sodium | 12 | $280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $168 | $42,74364 claims |
| Boehringer IngelheimSpiriva Respimat | $123 | $8,34213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 pulmonary disease providers in North Dakota.
Other pulmonary disease in Bismarck
- Alfredo IardinoBismarck$26K
- Bhaja ShresthaBismarck$10K
- Saurav PokharelBismarck$5K
- Nameer Al YousifBismarck$5K
- Marwan MashinaBismarck$3K
- Kamal MubarakBismarck$2K
- Eusebio DesuyoBismarck$2K
- Andreas SarrigiannidisBismarck$1K
- Monica PauloBismarck$118
- Shaher SamrahBismarck$92
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.